Irritable bowel syndrome (IBS) diagnostics market was valued at US$ 2,470.61 million in 2020 and is projected to reach US$ 3,880.91 million by 2028; it is expected to grow at a CAGR of 5.9% from 2021 to 2028.
Irritable bowel syndrome (IBS) is defined as a gastro-intestinal disorder causing discomfort in the stomach, along with diarrhea, and constipation. IBS can develop after a severe session of diarrhea (gastroenteritis) caused by bacteria or a virus. IBS might also be associated with a surplus of bacteria in the bowels (bacterial overgrowth). People exposed to stressful events, especially in childhood, tend to have more symptoms of IBS. IBS diagnostics is done through medical history, physical exam, and imaging tests. However, IBS is majorly diagnosed by lactose intolerance tests, breath test for bacterial overgrowth, blood test, and stool test. The tests are done based on symptoms such as constipation-predominant, diarrhea-predominant, or mixed. It can also detect by various imaging tests such as CT Scan or X-ray, upper endoscopy, and colonoscopy.
Download sample PDF Report at: https://www.theinsightpartners.com/sample/TIPRE00016657/
A few prominent players operating in the irritable bowel syndrome (IBS) diagnostics market are Commonwealth Diagnostics International; Genova Diagnostics; Gemelli Biotech; Prometheus Laboratories; Inova Diagnostics, Inc.; Biohit Oyj; Aerodiagnostics, LLC.; Metabolic Solutions, Inc.; Sysmex Corporation; and Bühlmann Laboratories AG, among others.
Irritable bowel syndrome (IBS) diagnostics market is segmented on the basis of diagnosis, indication, and geography. By geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis of the irritable bowel syndrome (IBS) diagnostics market, emphasizing on parameters such as market trends, technological advancements, and market dynamics along with the analysis of competitive landscape of world’s leading market players.
The COVID-19 pandemic is estimated to have a significant positive impact on the irritable bowel syndrome (IBS) diagnostics market. Majority of the pharmaceutical companies across the world are engaged in the development of vaccines for COVID-19. Moreover, irritable bowel syndrome (IBS) is frequently triggered by COVID-19 stress. Thus, home testing kits are preferable to laboratory testing as laboratory services may be overwhelmed in the pandemic, which is anticipated to have a positive impact on the other segments of the market in the coming months. However, disruptions in the supply chain caused due to the halt in global operations are hindering the market growth.
The report segments the global irritable bowel syndrome (IBS) diagnostics market as follows:
Irritable Bowel Syndrome (IBS) Diagnostics Market – by Diagnosis
Irritable Bowel Syndrome (IBS) Diagnostics Market – by Indication
Buy this Report Research @ https://www.theinsightpartners.com/buy/TIPRE00016657/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.